Last updated: September 23, 2026
Zoster vaccine live, marketed as Zostavax by Merck, was the first widely used shingles vaccine in the United States. Its commercial position deteriorated after GlaxoSmithKline launched Shingrix, a recombinant zoster vaccine with superior efficacy and a two-dose schedule. Merck discontinued U.S. distribution of Zostavax in November 2020 and stopped manufacturing the product globally after remaining inventory was exhausted. The product has no meaningful current U.S. revenue base, no active U.S. launch opportunity for a conventional generic, and limited residual value outside historical sales, intellectual property, and market-access analysis.
What is zoster vaccine live and how was Zostavax commercialized?
Zoster vaccine live contains a live attenuated varicella-zoster virus derived from the Oka/Merck strain. Merck developed the product for prevention of herpes zoster, commonly called shingles, and postherpetic neuralgia in older adults.
| Attribute |
Zostavax |
| Active biological component |
Live attenuated varicella-zoster virus, Oka/Merck strain |
| Sponsor |
Merck & Co., Inc. |
| U.S. brand |
Zostavax |
| FDA approval |
May 25, 2006 |
| Initial U.S. indication |
Prevention of herpes zoster in adults aged 60 and older |
| Later U.S. indication |
Adults aged 50 and older |
| Dosage form |
Single-dose subcutaneous vaccine |
| U.S. regulatory status |
No longer distributed |
| Primary commercial competitor |
Shingrix, GSK |
| Vaccine class |
Live attenuated viral vaccine |
The FDA initially approved Zostavax for adults aged 60 years and older based on the Shingles Prevention Study. The agency later expanded the indication to adults aged 50 years and older. Zostavax reduced shingles incidence but had lower and less durable protection than Shingrix, particularly in older adults (Food and Drug Administration [FDA], 2006, 2011).
When did Zostavax lose market exclusivity?
Zostavax lost practical market exclusivity through product competition before a meaningful generic or follow-on vaccine market developed. The key commercial event was the launch of Shingrix in 2017.
| Event |
Date |
Commercial effect |
| FDA approval of Zostavax |
May 2006 |
Established Merck’s U.S. shingles-vaccine franchise |
| FDA approval of Zostavax for adults 50 and older |
March 2011 |
Expanded eligible population |
| FDA approval of Shingrix |
October 2017 |
Introduced a higher-efficacy recombinant competitor |
| ACIP preferential recommendation for Shingrix |
October 2017 |
Accelerated substitution away from Zostavax |
| Merck announces U.S. discontinuation |
June 2020 |
Ended further U.S. distribution planning |
| Final U.S. distribution |
November 18, 2020 |
Removed Zostavax from the U.S. commercial channel |
| CDC recommendation |
Current guidance |
Shingrix is preferred; Zostavax is no longer available in the United States |
Zostavax did not face a classic small-molecule patent cliff. The product’s commercial decline resulted from clinical differentiation, public-health recommendations, supply decisions, and physician preference. Shingrix’s preferred status under the Advisory Committee on Immunization Practices shifted demand rapidly toward GSK’s product (Centers for Disease Control and Prevention [CDC], 2024).
What was the financial trajectory of Zostavax?
Merck’s public filings show a sharp decline in Zostavax revenue after Shingrix entered the market. Merck has not continued to report Zostavax as a material standalone product after discontinuation, so current revenue is effectively zero in the United States.
Publicly reported sales varied by reporting period and product classification. Merck’s annual reports historically included Zostavax within vaccine-product disclosures, and the product’s peak annual sales were in the high hundreds of millions of dollars before competitive erosion.
| Period |
Financial trajectory |
Main driver |
| 2006-2015 |
Growth and maturation |
First-mover shingles-vaccine position |
| 2016-2017 |
High-value mature product |
Established adult immunization demand |
| 2018 |
Rapid decline begins |
Shingrix launch and preferential clinical profile |
| 2019 |
Severe erosion |
Shingrix supply expansion and physician switching |
| 2020 |
Exit from U.S. market |
Merck discontinuation and inventory depletion |
| 2021 onward |
No material U.S. commercial trajectory |
Product unavailable in the U.S. |
Merck’s vaccine portfolio became increasingly concentrated in Gardasil/Gardasil 9, ProQuad, M-M-R II, Pneumovax 23, and other products. Zostavax no longer contributed materially to the company’s growth strategy after 2020. The financial impact was a product-level revenue loss rather than a material threat to Merck’s consolidated business, which was increasingly driven by Keytruda and other franchises (Merck & Co., Inc., 2017-2021).
How did Shingrix affect Zostavax sales?
Shingrix displaced Zostavax because it provided higher efficacy and did not use a live virus. In pivotal trials, Shingrix demonstrated approximately 97% efficacy against shingles in adults aged 50 years and older and approximately 91% efficacy in adults aged 70 years and older. Its protection also remained comparatively durable over follow-up periods reported by GSK and regulators (Lal et al., 2015).
Zostavax’s limitations included:
- Lower efficacy in older patients.
- Waning protection over time.
- Contraindication or precaution concerns for certain immunocompromised populations because it used a live attenuated virus.
- A less favorable position after ACIP recommended Shingrix over Zostavax.
- Supply and distribution disruption during the transition to Shingrix.
Shingrix’s two-dose regimen created an additional administration event but did not prevent substitution. The clinical benefit was sufficiently differentiated for U.S. prescribers, payers, and public-health authorities to favor GSK’s product.
What is the FDA and Orange Book status of Zostavax?
Zostavax was regulated as a vaccine biologic under a biologics license application, not as a conventional small-molecule drug. Its primary regulatory record was maintained through the FDA biologics framework.
The Orange Book is not the principal source for Zostavax’s regulatory exclusivity or patent information. The relevant records are the FDA biologics license, product labeling, vaccine approvals, and historical regulatory submissions. Zostavax did not generate a conventional ANDA-based generic-entry pathway because a live attenuated vaccine is not ordinarily substituted through a standard small-molecule ANDA.
The practical U.S. status is:
| Regulatory issue |
Status |
| FDA approval |
Historically approved |
| Current U.S. availability |
Not available |
| Current CDC use recommendation |
Not used; Shingrix is preferred |
| Standard ANDA generic pathway |
Not applicable |
| Biosimilar pathway |
Theoretical but commercially irrelevant for Zostavax |
| Orange Book relevance |
Limited |
| U.S. launch status |
Discontinued |
What patents protect Zostavax?
Zostavax was supported by a layered technology portfolio involving the Oka/Merck strain, attenuation methods, vaccine production, stabilization, formulation, and manufacturing controls. The commercial value of those rights has declined substantially because the branded product is no longer marketed in the United States.
The principal patent categories were:
| Patent category |
Relevance to Zostavax |
Current commercial significance |
| Oka/Merck strain and biological materials |
Defines or supports the vaccine strain |
Reduced after expiration and product discontinuation |
| Attenuation and propagation methods |
Supports development and manufacture |
Potentially relevant only to legacy or related products |
| Vaccine formulation and stabilizers |
Supports potency and shelf-life |
Limited after U.S. withdrawal |
| Lyophilization and reconstitution |
Supports product presentation |
Low current value |
| Manufacturing processes |
Creates technical barriers to reproducing the product |
More important than conventional formulation patents |
| Use patents |
Cover vaccination of eligible populations |
Weak after product withdrawal and loss of market |
Specific patent-by-patent conclusions require a jurisdiction-specific family search because patent scope, terminal disclaimers, continuations, and regulatory exclusivity differ across the United States, Europe, Japan, and other markets. A current U.S. commercial launch does not appear viable even where historical patent protection may have existed, because Zostavax is no longer supplied and Shingrix has become the market standard.
Does Zostavax face biosimilar or generic competition?
Zostavax does not face a conventional biosimilar launch threat in the way a monoclonal antibody does. A follow-on developer would need to reproduce a live attenuated viral vaccine with comparable identity, purity, potency, consistency, manufacturing control, and clinical performance.
A potential follow-on product would encounter:
- Complex cell-culture and viral-seed controls.
- Extensive comparability testing.
- Clinical and immunogenicity requirements.
- Cold-chain and stability requirements.
- Manufacturing-site validation.
- Limited commercial demand in the United States.
- A dominant incumbent, Shingrix, with a stronger clinical position.
The economic incentive is therefore weak. A lower-cost live vaccine would still need to overcome a preferred recombinant competitor and establish payer, provider, and public-health acceptance.
What patent litigation affected Zostavax?
Zostavax did not experience a major U.S. patent-litigation cycle comparable to products such as Humira, Revlimid, or Keytruda. The material legal risks were more closely associated with product-liability claims, vaccine-injury allegations, manufacturing issues, and competitive replacement than with Paragraph IV litigation.
No standard Paragraph IV launch campaign has defined the Zostavax market. That is consistent with the product’s biologic status, the absence of a conventional ANDA market, and the lack of commercial incentive to challenge a discontinued vaccine.
Which companies are challenging the Zostavax franchise?
GSK was the principal commercial challenger through Shingrix. Other shingles-vaccine competition has been limited.
| Company |
Product |
Competitive position |
| Merck |
Zostavax |
Historical live attenuated vaccine; discontinued in the U.S. |
| GSK |
Shingrix |
Preferred U.S. shingles vaccine |
| Regional vaccine developers |
Various candidates or legacy products |
Limited impact on the U.S. market |
Shingrix is not a biosimilar or generic version of Zostavax. It is a differentiated recombinant vaccine using varicella-zoster virus glycoprotein E with an adjuvant system. Its commercial success came from clinical superiority and guideline preference rather than direct molecule-level substitution.
What generic launch risks existed for Zostavax?
The principal generic launch risk was low. The more serious risk was product displacement by a clinically superior vaccine.
Patent and regulatory risk
Patent expiry could have reduced barriers to a follow-on live vaccine, but it would not have solved the regulatory and manufacturing burden. A follow-on developer would still need a viable biologics approval strategy and a commercial reason to enter.
Manufacturing risk
Live-virus production creates meaningful technical barriers. Potency, attenuation, contamination control, viral seed management, and stability must be tightly controlled. These factors are harder to replicate than a conventional tablet formulation.
Market risk
The U.S. market had already shifted toward Shingrix. Even a technically successful Zostavax follow-on would likely face inferior clinical positioning and limited reimbursement leverage.
Commercial launch scenarios
| Scenario |
Probability assessment |
Market effect |
| Conventional U.S. generic launch |
Low |
No meaningful impact |
| Follow-on live attenuated vaccine |
Low |
Possible price competition in selected markets |
| Regional reintroduction of Zostavax |
Low |
Dependent on local regulatory and supply conditions |
| Continued Shingrix dominance |
High |
Maintains GSK’s market position |
| New non-Shingrix vaccine entrant |
Possible over longer term |
Depends on efficacy and immunocompromised-patient data |
How strong is the Zostavax patent estate?
The historical patent estate was strategically useful but is no longer a strong commercial defense in the United States. Patent strength must be separated into four categories:
| Dimension |
Assessment |
| Product composition |
Limited current value because the product is discontinued |
| Manufacturing know-how |
Still technically meaningful |
| Formulation and presentation |
Likely narrower and less valuable than core manufacturing knowledge |
| Market exclusivity |
Effectively ended through commercial withdrawal and competitor preference |
Trade secrets and manufacturing know-how may remain more valuable than expired or expiring patent claims. However, those assets have limited licensing value unless a company intends to develop a new live attenuated zoster vaccine or use related varicella-zoster technology.
What licensing deals involve Zostavax?
There is no widely disclosed current licensing transaction that has restored Zostavax as a commercial growth asset. Merck’s core value came from internal development, manufacturing, and commercialization of the Oka/Merck strain and related vaccine technology.
Potential residual licensing value could involve:
- Historical strain technology.
- Manufacturing processes.
- Technology transfer for regional vaccine production.
- Know-how related to live attenuated varicella-zoster vaccines.
- Archival clinical and regulatory data.
The economic value of any license would be constrained by Shingrix’s market position, the declining role of live vaccines in immunocompromised populations, and the lack of U.S. product availability.
How does Zostavax compare with Shingrix?
| Metric |
Zostavax |
Shingrix |
| Sponsor |
Merck |
GSK |
| Vaccine type |
Live attenuated |
Recombinant, adjuvanted |
| Dosing |
One dose |
Two doses |
| U.S. approval |
2006 |
2017 |
| Efficacy |
Lower, especially with age |
Approximately 90% or higher in pivotal studies |
| Use in immunocompromised adults |
Restricted because of live-virus platform |
Broadly positioned for immunocompromised adults |
| Current U.S. availability |
Discontinued |
Available |
| Market position |
Historical |
Standard of care |
| Generic risk |
Low |
Low in the near term |
| Commercial outlook |
No meaningful U.S. growth |
Established growth and replacement franchise |
The comparison explains the financial transfer from Merck to GSK in the shingles-vaccine category. Zostavax was a mature product whose clinical limitations became more important after a superior alternative became available.
What is the geographic status of Zostavax?
Zostavax is no longer a meaningful U.S. commercial product. Availability in other jurisdictions has also contracted, with discontinuation decisions varying by country, inventory, and regulatory status. Product availability should not be inferred from historical marketing authorization alone.
Geographic commercial value is limited by:
- Local approval status.
- Remaining inventory.
- National immunization recommendations.
- Availability of Shingrix.
- Cold-chain infrastructure.
- Willingness to use a live vaccine.
- Local manufacturing and supply agreements.
The product’s residual value is therefore regional rather than global, and it is primarily historical.
Key Takeaways
- Zostavax was the first major U.S. shingles vaccine and generated substantial revenue for Merck before 2017.
- Shingrix displaced Zostavax through higher efficacy, greater durability, and preferential ACIP recommendations.
- Merck ended U.S. distribution on November 18, 2020.
- Zostavax has no meaningful current U.S. revenue trajectory.
- The product is regulated as a biologic vaccine, so the Orange Book and ANDA pathways are not central.
- Conventional generic competition was never the primary threat.
- A follow-on live attenuated vaccine would face major manufacturing, clinical, regulatory, and commercial barriers.
- Zostavax’s historical patent and know-how estate may retain limited licensing value, but it no longer provides a meaningful U.S. commercial defense.
- GSK’s Shingrix is the dominant commercial product in the shingles-vaccine market.
FAQs About Zostavax Market Value and Exclusivity
Is Zostavax still available in the United States?
No. Merck stopped distributing Zostavax in the United States on November 18, 2020. Shingrix is the U.S. vaccine recommended for shingles prevention.
Can a generic company launch a generic Zostavax?
A conventional generic launch is unlikely because Zostavax is a live biologic vaccine rather than a small-molecule drug. A follow-on manufacturer would need a separate biologics development and approval strategy.
Did Shingrix make Zostavax obsolete?
Commercially, yes. Shingrix’s higher efficacy and preferred public-health status caused rapid substitution and removed Zostavax’s growth opportunity.
Does Zostavax still have patent value?
Some historical manufacturing know-how, strain technology, and regulatory information may retain value. The patent estate has little practical value for the U.S. market because the product is discontinued.
What was the main cause of Zostavax’s revenue decline?
The main cause was competitive displacement by Shingrix, reinforced by ACIP’s preference for Shingrix and the clinical limitations of the live attenuated platform.
References
Centers for Disease Control and Prevention. (2024). Shingles vaccination: What everyone should know. https://www.cdc.gov/shingles/vaccination.html
Food and Drug Administration. (2006). Zostavax approval letter and prescribing information. U.S. Department of Health and Human Services. https://www.fda.gov
Food and Drug Administration. (2011). Zostavax label expansion for adults aged 50 through 59 years. U.S. Department of Health and Human Services. https://www.fda.gov
GlaxoSmithKline Biologicals. (2017). Shingrix prescribing information. U.S. Food and Drug Administration.
Lal, H., Cunningham, A. L., Godec, E. Z., Chlibek, R., Diez-Domingo, J., Hwang, S. J., Levin, M. J., McElhaney, J. E., Poder, A., Puig-Barberà, J., Vanden Abeele, C., Vesikari, T., Watanabe, D., Zahaf, T., Heineman, T. C., & ZOE-50 Study Group. (2015). Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine, 372(22), 2087-2096. https://doi.org/10.1056/NEJMoa1501184
Merck & Co., Inc. (2017). 2017 annual report. https://www.merck.com/annual-reports/
Merck & Co., Inc. (2018). 2018 annual report. https://www.merck.com/annual-reports/
Merck & Co., Inc. (2019). 2019 annual report. https://www.merck.com/annual-reports/
Merck & Co., Inc. (2020). 2020 annual report. https://www.merck.com/annual-reports/
Merck & Co., Inc. (2021). 2021 annual report. https://www.merck.com/annual-reports/
